Back to Search
Start Over
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging
- Source :
- Motsinger-Reif, Alison A; Zhu, Hongjie; Kling, Mitchel A; Matson, Wayne; Sharma, Swati; Fiehn, Oliver; et al.(2013). Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer¿s disease from normal cognitive aging. Acta Neuropathologica Communications, 1(1), 28. doi: http://dx.doi.org/10.1186/2051-5960-1-28. Retrieved from: http://www.escholarship.org/uc/item/3b07n7d5, Acta Neuropathologica Communications
- Publisher :
- Springer Nature
-
Abstract
- Background A critical and as-yet unmet need in Alzheimer disease (AD) research is the development of novel markers that can identify individuals at risk for cognitive decline due to AD. This would aid intervention trials designed to slow the progression of AD by increasing diagnostic certainty, and provide new pathophysiologic clues and potential drug targets. Results We used two metabolomics platforms (gas chromatography-time of flight mass spectrometry [GC-TOF] and liquid chromatography LC-ECA array [LC-ECA]) to measure a number of metabolites in cerebrospinal fluid (CSF) from patients with AD dementia and from cognitively normal controls. We used stepwise logistic regression models with cross-validation to assess the ability of metabolite markers to discriminate between clinically diagnosed AD participants and cognitively normal controls and we compared these data with traditional CSF Luminex immunoassay amyloid-β and tau biomarkers. Aβ and tau biomarkers had high accuracy to discriminate cases and controls (testing area under the curve: 0.92). The accuracy of GC-TOF metabolites and LC-ECA metabolites by themselves to discriminate clinical AD participants from controls was high (testing area under the curve: 0.70 and 0.96, respectively). Conclusions Our study identified several CSF small-molecule metabolites that discriminated especially well between clinically diagnosed AD and control groups. They appear to be suitable for further confirmatory and validation studies, and show the potential to provide predictive performance for AD.
- Subjects :
- Male
Aging
medicine.medical_specialty
Neurology
Metabolite
tau Proteins
Disease
Neuropsychological Tests
Bioinformatics
Gas Chromatography-Mass Spectrometry
Dementias
Pathology and Forensic Medicine
Diagnosis, Differential
03 medical and health sciences
Cellular and Molecular Neuroscience
chemistry.chemical_compound
Cognition
0302 clinical medicine
Metabolomics
Cerebrospinal fluid biomarkers
Alzheimer Disease
medicine
Humans
Dementia
Stepwise logistic regression
Cognitive decline
Aged
030304 developmental biology
0303 health sciences
Amyloid beta-Peptides
business.industry
Research
Area under the curve
medicine.disease
3. Good health
Logistic Models
chemistry
Area Under Curve
Female
Neurology (clinical)
Alzheimer's disease
business
Alzheimer’s disease
Biomarkers
030217 neurology & neurosurgery
Chromatography, Liquid
Subjects
Details
- Language :
- English
- ISSN :
- 20515960
- Volume :
- 1
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Acta Neuropathologica Communications
- Accession number :
- edsair.doi.dedup.....645aab2da1731dfa1e5062ebc3687de2
- Full Text :
- https://doi.org/10.1186/2051-5960-1-28